Efficacy and safety of 24 weeks treatment with oral TLR8 agonist, selgantolimod, in virally-suppressed adult patients with chronic hepatitis B: a phase 2 study

Authors
Category Primary study
JournalJournal of Hepatology
Year 2020
This article has no abstract
Epistemonikos ID: 5603e7870230d0415bd05bfb016260cdfc300726
First added on: Nov 24, 2021